EuroPCR 2024 | Complete revascularization affects clinical outcomes? REVIVED.BCIS2 Insights

Complete revascularization has shown in several studies and meta-analysis a benefit in mortality vs. incomplete revascularization.

The REVIVED-BCIS looked at whether there were differences in mortality and hospitalization for cardiac failure in patients with ventricular function deterioration and viability when comparing coronary angioplasty(PCI) against optimal medical treatment. This study showed that PCI was not associated with significant changes in the established final outcomes. 

Of 266 patients undergoing PCI, 130 received complete revascularization and 136 incomplete revascularization. Complete revascularization was defined as anatomical according to coronary revascularization index (Δ Score BCIS), or viability guided, according to myocardial revascularization index.

In terms of anatomical revascularization, there were no significant differences between incomplete anatomical revascularization and optimal medical treatment (HR 0.97; P=0.85). Also, complete anatomical revascularization did not show significant differences (HR 0.90; P=0.59).

Read also: EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis.

When looking at viability guided revascularization, neither were there differences in favor of revascularization vs optimal medical treatment, both with complete (HR 0.95; p=0.76) and incomplete revascularization (HR 0.83; p=0.28).

Authors’ conclusion: The REVIVED-BCIS2, on patients with stable coronary artery disease and severe ventricular dysfunction, neither complete anatomical revascularization or viability guided revascularization generated changes in clinical events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Margaret Mcentegart, at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...